TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer,...